Table 3 Therapeutic approaches according to patient age.
Variable | Overall (total n = 319) | Non-neonatal episodes (>3 m) (total n = 213) | Neonatal episodes (≤3 m) (total n = 106) | P value¶ |
|---|---|---|---|---|
Initial antifungal therapy* | <0.001 | |||
Fluconazole/Voriconazole | 210 (65.8) | 154 (72.3) | 56 (52.8) | |
Amphotericin B | 86 (27.0) | 42 (19.7) | 44 (41.5) | |
Echinocandin-based regimen | 14 (4.4) | 11 (5.2) | 3 (2.8) | |
Final treatment regimens | <0.001 | |||
Fluconazole/Voriconazole | 122 (38.2) | 90 (42.3) | 32 (30.2) | |
Amphotericin B | 94 (29.5) | 47 (22.1) | 47 (44.3) | |
Echinocandin-based regimen | 87 (27.3) | 68 (31.9) | 19 (17.9) | |
Combination antifungal treatment | 7 (2.2) | 2 (0.9) | 5 (4.7) | |
No treatment | 9 (2.8) | 6 (2.8) | 3 (2.8) | |
Initiation of effective antifungal agents within 24 hours | 131 (41.1) | 97 (45.5) | 34 (32.1) | 0.021 |
Initiation of effective antifungal agents within 48 hours | 221 (69.3) | 156 (73.2) | 65 (61.3) | 0.033 |
Breakthrough candidemia | 45 (14.1) | 33 (15.5) | 12 (11.3) | 0.394 |
Central venous catheter (CVC) removal | ||||
CVC removal within 48 hours | 83/310 (26.8) | 59/213 (27.7) | 24/106 (22.6) | 0.784 |
CVC removal within 72 hours | 115/310 (37.1) | 77/208 (37.0) | 38/102 (37.2) | 0.530 |
Elective CVC removal (after 72 hours of onset) | 68/310 (21.3) | 55/213 (25.8) | 13/106 (12.3) | 0.029 |
CVC removal after persistent candidemia | 22/310 (7.1) | 14/213 (6.6) | 8/106 (7.5) | 0.988 |
